AU2012205547B2 - Lipid-lowering antidiabetic agent - Google Patents

Lipid-lowering antidiabetic agent Download PDF

Info

Publication number
AU2012205547B2
AU2012205547B2 AU2012205547A AU2012205547A AU2012205547B2 AU 2012205547 B2 AU2012205547 B2 AU 2012205547B2 AU 2012205547 A AU2012205547 A AU 2012205547A AU 2012205547 A AU2012205547 A AU 2012205547A AU 2012205547 B2 AU2012205547 B2 AU 2012205547B2
Authority
AU
Australia
Prior art keywords
metformin
diabetes
subject
compound
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012205547A
Other languages
English (en)
Other versions
AU2012205547A1 (en
Inventor
Banavara L. Mylari
Frank C. Sciavolino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thetis Pharmaceuticals LLC
Original Assignee
Thetis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thetis Pharmaceuticals LLC filed Critical Thetis Pharmaceuticals LLC
Publication of AU2012205547A1 publication Critical patent/AU2012205547A1/en
Application granted granted Critical
Publication of AU2012205547B2 publication Critical patent/AU2012205547B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/52—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Endocrinology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012205547A 2011-01-12 2012-01-12 Lipid-lowering antidiabetic agent Ceased AU2012205547B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161461113P 2011-01-12 2011-01-12
US61/461,113 2011-01-12
US13/348,265 US20120178813A1 (en) 2011-01-12 2012-01-11 Lipid-lowering antidiabetic agent
US13/348,265 2012-01-11
PCT/US2012/021070 WO2012097144A1 (en) 2011-01-12 2012-01-12 Lipid-lowering antidiabetic agent

Publications (2)

Publication Number Publication Date
AU2012205547A1 AU2012205547A1 (en) 2013-08-01
AU2012205547B2 true AU2012205547B2 (en) 2015-08-27

Family

ID=46455756

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012205547A Ceased AU2012205547B2 (en) 2011-01-12 2012-01-12 Lipid-lowering antidiabetic agent

Country Status (12)

Country Link
US (4) US20120178813A1 (enExample)
EP (1) EP2663186A4 (enExample)
JP (1) JP5911514B2 (enExample)
KR (1) KR20140092228A (enExample)
CN (1) CN103533833B (enExample)
AU (1) AU2012205547B2 (enExample)
BR (1) BR112013017845A2 (enExample)
CA (1) CA2824192A1 (enExample)
EA (1) EA201391028A1 (enExample)
IL (1) IL227346A0 (enExample)
MX (1) MX2013008131A (enExample)
WO (1) WO2012097144A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
MX2015000408A (es) * 2012-07-10 2015-07-14 Thetis Pharmaceuticals Llc Forma de triple sal de metformina.
WO2014080307A2 (en) * 2012-11-21 2014-05-30 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
AU2014276346A1 (en) * 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014195810A2 (en) * 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
EP3140316A1 (en) * 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
EP3157936B1 (en) 2014-06-18 2018-10-17 Thetis Pharmaceuticals LLC Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016132186A1 (en) * 2015-02-20 2016-08-25 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
US9371276B1 (en) * 2015-03-21 2016-06-21 Mohan Murali Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2017210604A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation
EP3648748A1 (en) 2017-07-06 2020-05-13 Evonik Operations GmbH Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts
BR112020003255A2 (pt) 2017-08-15 2020-08-18 Evonik Operations Gmbh comprimidos com alto teor de ingrediente ativo de sais de aminoácido graxo ômega-3
US11497722B2 (en) * 2017-12-18 2022-11-15 Soochow University Use of metformin salt in the treatment of cerebral infarction
EP4009961A1 (en) 2019-08-08 2022-06-15 Evonik Operations GmbH Solubility enhancement of poorly soluble actives
MX2022001570A (es) 2019-08-08 2022-03-02 Evonik Operations Gmbh Proceso de flujo descendente para la produccion de sales de acidos grasos poliinsaturados.
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN116999398A (zh) * 2022-06-30 2023-11-07 山东海赜生物科技有限公司 一种口服组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041923A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of metformin
US20050182029A1 (en) * 2002-02-14 2005-08-18 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
DE60124504T2 (de) 2000-02-04 2007-09-20 Takeda Pharmaceutical Co. Ltd. Stabile emulsionszubereitungen
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
FR2818906B1 (fr) * 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
DE10102050A1 (de) 2001-01-17 2002-07-18 Basf Ag Zubereitung zur Verbesserung der Nahrungsverwertung
EP1373182A1 (de) 2001-03-29 2004-01-02 Basf Aktiengesellschaft Konjugierte ungesättigte glyceridgemische und verfahren zur ihrer herstellung
ATE451928T1 (de) 2001-08-31 2010-01-15 Univ Rutgers Verfahren zur behandlung von krankheiten mit pflanzenextrakten
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP1558237A4 (en) * 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED GLYCEMIC REGULATION IN PREDIABETE AND / OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
CA2516142A1 (en) * 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20080045559A1 (en) 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US7223770B2 (en) 2003-10-29 2007-05-29 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
AU2005205882A1 (en) 2004-01-22 2005-08-04 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
WO2005118612A1 (en) 2004-06-04 2005-12-15 Sonus Pharmaceuticals, Inc. Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
EP1833313A2 (en) * 2004-10-15 2007-09-19 Corporation Limited Photonz Compositions containing high omega-3 and low saturated fatty acid levels
WO2006046156A2 (en) 2004-10-29 2006-05-04 Joan Campbell-Tofte Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and methods of using same
AU2006264407B2 (en) 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
WO2007056281A2 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
US20070213298A1 (en) * 2006-02-07 2007-09-13 Universitetet I Oslo Omega 3
CA2638787A1 (en) 2006-02-16 2007-08-23 Takeda Pharmaceutical Company Limited Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
US20090047340A1 (en) 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
WO2007149313A1 (en) 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
CA2667211A1 (en) 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
WO2008058274A2 (en) * 2006-11-09 2008-05-15 Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
EP2109447B1 (en) * 2007-01-29 2015-06-10 HanAll Biopharma Co., Ltd. N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
AR066268A1 (es) 2007-04-27 2009-08-05 Takeda Pharmaceutical Compuesto de imidazol sustituido y su uso
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
CN101855204B (zh) * 2007-09-21 2013-09-11 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
CN103373985B (zh) 2008-06-19 2015-10-28 武田药品工业株式会社 杂环化合物及其用途
NZ720946A (en) * 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
AU2013277441B2 (en) 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182029A1 (en) * 2002-02-14 2005-08-18 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
WO2005041923A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of metformin

Also Published As

Publication number Publication date
US9012507B2 (en) 2015-04-21
US20120178813A1 (en) 2012-07-12
US20140107360A1 (en) 2014-04-17
WO2012097144A1 (en) 2012-07-19
US20150051284A1 (en) 2015-02-19
MX2013008131A (es) 2014-01-08
CN103533833A (zh) 2014-01-22
BR112013017845A2 (pt) 2019-09-24
EP2663186A4 (en) 2014-09-24
US8901107B2 (en) 2014-12-02
US20130281535A1 (en) 2013-10-24
KR20140092228A (ko) 2014-07-23
JP2014512333A (ja) 2014-05-22
EP2663186A1 (en) 2013-11-20
EA201391028A1 (ru) 2013-12-30
JP5911514B2 (ja) 2016-04-27
AU2012205547A1 (en) 2013-08-01
US9216951B2 (en) 2015-12-22
CN103533833B (zh) 2016-08-31
IL227346A0 (en) 2013-09-30
CA2824192A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
AU2012205547B2 (en) Lipid-lowering antidiabetic agent
US7973073B2 (en) Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
US20220249463A1 (en) Methods of altering cardiac remodeling using compounds that promote glucose oxidation
US8933124B2 (en) Tri-salt form of metformin
US8853259B2 (en) Metformin derivatives for treating diabetes and diabetes complications
US20140024708A1 (en) Ursolic acid salts for treating diabetes and obesity
WO2014011814A1 (en) Tri-salt form of metformin
TW516959B (en) Composition containing ascorbic acid
WO2014008374A2 (en) Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
US8440723B2 (en) Metformin salts of salicylic acid and its congeners
US9382187B2 (en) Tri-salt form of metformin
CN100486960C (zh) 双胍类衍生物及其制备方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired